



CADTH Reference List

Stellate Ganglion Block for the Treatment of Posttraumatic Stress Disorder, Depression, and Anxiety: A 2023 Update

May 2023

Authors: Camille Santos, Monika Mierzwinski-Urban

Contributor: Weiyi Xie

Cite As: *Stellate Ganglion Block for the Treatment of Posttraumatic Stress Disorder, Depression, and Anxiety: A 2023 Update*. (CADTH reference list: summary of abstracts). Ottawa: CADTH; 2023 May.

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up to date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to requests@cadth.ca

Key Messages

- We did not find any relevant literature about the clinical effectiveness of stellate ganglion block for the treatment of posttraumatic stress disorder.
- We found 1 randomized controlled trial about the clinical effectiveness of stellate ganglion block for the treatment of depression or anxiety.
- We did not find any relevant evidence-based guidelines about the use of stellate ganglion block for the treatment of posttraumatic stress disorder, depression, or anxiety.

Research Questions

1. What is the clinical effectiveness of stellate ganglion block for the treatment of posttraumatic stress disorder?
2. What is the clinical effectiveness of stellate ganglion block for the treatment of depression or anxiety?
3. What are the evidence-based clinical practice guidelines regarding the use of stellate ganglion block for the treatment of posttraumatic stress disorder, depression, or anxiety?

Methods

Literature Search Methods

The literature search strategy used in this report is an update of 1 developed for a previous CADTH report with additional terms included. For the current report, an information specialist conducted a literature search on key resources including MEDLINE, PsycInfo, the Cochrane Database of Systematic Reviews, the International HTA Database, Canadian and major international health technology agencies, as well as a focused internet search. The search approach was customized to retrieve a limited set of results, balancing comprehensiveness with relevancy. The initial search was limited to English-language documents published between January 1, 2016, and January 21, 2021. For the current report, database searches were rerun on May 24, 2023, to capture any articles published or made available since January 1, 2016. The search of major health technology agencies was also updated to include documents published since January 2021.

Selection Criteria and Summary Methods

One reviewer screened literature search results (titles and abstracts) and selected publications according to the inclusion criteria presented in [Table 1](#). Full texts of study publications were not reviewed. The Overall Summary of Findings was based on information available in the abstracts of selected publications. Open access full-text versions of evidence-based guidelines were reviewed when available, and relevant recommendations were summarized.

Table 1: Selection Criteria

Criteria	Description
Population	Q1 and Q3: Individuals (any age) with PTSD Q2 and Q3: Individuals (any age) with depression (any type) or an anxiety disorder
Intervention	Stellate ganglion block (i.e., anesthetic [any kind] injection into the stellate ganglion)
Comparator	Q1: Standard or usual treatments for PTSD (e.g., pharmacological, psychological therapies), placebo, no treatment (safety outcomes only) Q2: Standard or usual treatments for depression and anxiety (e.g., pharmacological, psychological therapies), placebo, no treatment (safety outcomes only) Q3: Not applicable
Outcomes	Q1 and Q2: Clinical benefits and harms (e.g., remission of PTSD, PTSD symptoms, anxiety, depression, functional status, quality of life, hematoma, accidental injection of anesthetic into wrong space [e.g., intravascular, brachial plexus], allergic response, muscle spasm, infection) Q3: Recommendations regarding best practices (e.g., treatment protocols, who should be treated, counter indications for treatment)
Study designs	Health technology assessments, systematic reviews, randomized controlled trials, nonrandomized studies, evidence-based guidelines

PTSD = posttraumatic stress disorder.

Results

One randomized controlled trial was identified regarding the clinical effectiveness of stellate ganglion block (SGB) for the treatment of depression or anxiety.¹ No relevant health technology assessments, systematic reviews, randomized controlled trials, or nonrandomized studies regarding the clinical effectiveness of SGB for the treatment of posttraumatic stress disorder were identified. Additionally, no relevant evidence-based guidelines regarding the use of SGB for the treatment of posttraumatic stress disorder, depression, or anxiety were identified.

Additional references of potential interest that did not meet the inclusion criteria are provided in [Appendix 1](#).

Overall Summary of Findings

One feasibility randomized controlled trial was identified regarding the clinical effectiveness of SGB for treatment-resistant depression.¹ The study found that individuals receiving bupivacaine injections at the stellate ganglion demonstrated a decrease in Montgomery-Asberg Depression Rating Scale scores after 42 days.¹ The same effect was observed in the control group.¹ Additionally, the adverse events observed in the same study were mild and temporary.¹

No relevant literature was found regarding the clinical effectiveness of SGB for the treatment of posttraumatic stress disorder and no relevant evidence-based guidelines regarding the use of SGB for the



treatment of posttraumatic stress disorder, depression, or anxiety were identified; therefore, no summary can be provided.



References

Health Technology Assessments

No literature identified.

Systematic Reviews

No literature identified.

Randomized Controlled Trials

1. Sussman D, Tassone VK, Nezhad FG, et al. Feasibility RCT of stellate ganglion block for treatment-resistant depression. *Chronic Stress (Thousand Oaks)*. Jan-Dec 2023;7:24705470231160315. [PubMed](#)

Nonrandomized Studies

No literature identified.

Guidelines and Recommendations

No literature identified.

Appendix 1: References of Potential Interest

Previous CADTH Reports

Li Y, Loshak H. CADTH health technology review: stellate ganglion block for the treatment of post-traumatic stress disorder, depression, and anxiety. *Can J Health Technol.* 2021;1(3). <https://www.cadth.ca/sites/default/files/pdf/htis/2021/RC1339%20SGB%20PTSD%20Final.pdf>. Accessed 2023 May 25.

Systematic Reviews

Unclear Comparator

Kerzner J, Liu H, Demchenko I, et al. Stellate ganglion block for psychiatric disorders: a systematic review of the clinical research landscape. *Chronic Stress (Thousand Oaks).* Jan-Dec 2021;5:24705470211055176. [PubMed](#)

Nonrandomized Studies

Case Studies or Reports

Kuo J, Nicklay M. Botox-enhanced stellate ganglion blockade for the treatment of post-traumatic stress disorder. *Cureus.* Apr 2023;15(4):e37573. [PubMed](#)

Lipov E, Sethi Z, Nandra G, Frueh C. Efficacy of combined subanesthetic ketamine infusion and cervical sympathetic blockade as a symptomatic treatment of PTSD/TBI in a special forces patient with a 1-year follow-up: a case report. *Heliyon.* Apr 2023;9(4):e14891. [PubMed](#)

Xu Y, Zhang Y. Treatment of multiple physiological and psychological disorders in one patient with stellate ganglion block: a case report. *J Int Med Res.* Jan 2021;49(1):300060520985645. [PubMed](#)
Not Specific to Stellate Ganglion Block

Lipov EG, Jacobs R, Springer S, Candido KD, Knezevic NN. Utility of cervical sympathetic block in treating post-traumatic stress disorder in multiple cohorts: a retrospective analysis. *Pain Physician.* 01 2022;25(1):77-85. [PubMed](#)

Peterson AL, Straud CL, Young-McCaughan S, et al. Combining a stellate ganglion block with prolonged exposure therapy for posttraumatic stress disorder: a nonrandomized clinical trial. *J Trauma Stress.* 12 2022;35(6):1801-1809. [PubMed](#)

Alternative Comparator

Mulvaney SW, Lynch JH, Curtis KE, Ibrahim TS. The successful use of left-sided stellate ganglion block in patients that fail to respond to right-sided stellate ganglion block for the treatment of post-traumatic stress disorder symptoms: a retrospective analysis of 205 patients. *Mil Med.* 07 01 2022;187(7-8):e826-e829. [PubMed](#)

Unclear Methods

Bajor LA, Balsara C, Osser DN. An evidence-based approach to psychopharmacology for posttraumatic stress disorder (PTSD) - 2022 update. *Psychiatry Res.* 11 2022;317():114840. [PubMed](#)

Review Articles

Kirkpatrick K, Khan MH, Deng Y, Shah KB. A review of stellate ganglion block as an adjunctive treatment modality. *Cureus.* Feb 2023;15(2):e35174. [PubMed](#)

Additional References

Evidence Repository

O'Neil ME, Cheney TP, Yu Y, et al. Pharmacologic and nonpharmacologic treatments for posttraumatic stress disorder: 2022 update of the PTSD-repository evidence base. Systematic review. Rockville (MD): Agency for Healthcare Research Quality; 2022. <https://effectivehealthcare.ahrq.gov/products/ptsd-pharm-non-pharm-treatment/research>. Accessed 2023 May 25.

Qualitative Study – Clinician Attitudes and Recommendations

Lynch JH, Muench PD, Okiishi JC, Means GE, Mulvaney SW. Behavioral health clinicians endorse stellate ganglion block as a valuable intervention in the treatment of trauma-related disorders. *J Investig Med.* 06 2021;69(5):989-993. [PubMed](#)